Septerna (NASDAQ:SEPN) SVP Daniel Long Sells 3,333 Shares

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,333 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total value of $126,087.39. Following the transaction, the senior vice president owned 96,412 shares in the company, valued at $3,647,265.96. This represents a 3.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Septerna Trading Down 1.9%

Shares of NASDAQ SEPN opened at $36.80 on Friday. The stock has a market cap of $1.72 billion, a P/E ratio of -68.15 and a beta of 2.30. Septerna, Inc. has a twelve month low of $13.67 and a twelve month high of $51.10. The stock has a 50 day moving average of $37.46 and a two-hundred day moving average of $31.15.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The business had revenue of $26.75 million for the quarter, compared to analysts’ expectations of $19.22 million. As a group, research analysts predict that Septerna, Inc. will post -1.41 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. HC Wainwright upped their target price on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Wells Fargo & Company raised their price target on Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Truist Financial boosted their price target on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th. Finally, Guggenheim increased their price objective on Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.44.

Institutional Trading of Septerna

Several hedge funds have recently made changes to their positions in SEPN. Deutsche Bank AG increased its stake in shares of Septerna by 5.3% during the fourth quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock worth $415,000 after acquiring an additional 744 shares during the period. Global Retirement Partners LLC acquired a new stake in Septerna in the fourth quarter valued at about $35,000. JPMorgan Chase & Co. boosted its holdings in Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after purchasing an additional 1,315 shares in the last quarter. PharVision Advisers LLC increased its position in Septerna by 17.5% during the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after purchasing an additional 1,780 shares during the period. Finally, Nuveen LLC increased its position in Septerna by 7.7% during the 4th quarter. Nuveen LLC now owns 25,798 shares of the company’s stock worth $719,000 after purchasing an additional 1,837 shares during the period.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.